Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News
EchoIQ von 3 Analysehäusern als "Best-in-Class" bewertet - Kurszielpotenzial von über 200?%
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DK8U | ISIN: LU2458332611 | Ticker-Symbol: Z45
Frankfurt
07.07.25 | 15:29
7,860 Euro
+1,03 % +0,080
1-Jahres-Chart
ALVOTECH Chart 1 Jahr
5-Tage-Chart
ALVOTECH 5-Tage-Chart
RealtimeGeldBriefZeit
7,6007,78015:59

Aktuelle News zur ALVOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ALVOTECH Aktie jetzt für 0€ handeln
SoAlvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma3
FrAlvotech: Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers4
MiAlvotech: Granting of Stock Options and Vesting of Restricted Share Units3
DiAlvotech - 6-K, Report of foreign issuer3
DiAlvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia (certolizumab pegol)370REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
► Artikel lesen
26.06.Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility6
25.06.Alvotech: Main Results of 2025 Annual and Extraordinary General Meeting112REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt...
► Artikel lesen
25.06.Alvotech reports positive results in study for Xolair biosimilar3
25.06.Alvotech: Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab)298REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines...
► Artikel lesen
23.06.Bayer's Eylea market grip set to slip as Alvotech biosimilar closes in95
23.06.Alvotech - 6-K, Report of foreign issuer3
23.06.European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept)413REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
► Artikel lesen
12.06.Alvotech - 6-K, Report of foreign issuer16
11.06.Alvotech schließt Privatplatzierung mit 40 institutionellen Investoren ab8
11.06.Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors686Alvotech (NASDAQ: ALVO, ALVO-SDB, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion...
► Artikel lesen
11.06.Alvotech auf Goldman Sachs Konferenz: Strategisches Wachstum bei Biosimilars5
06.06.Alvotech and Dr. Reddy's partner for Keytruda biosimilar3
05.06.Alvotech - 6-K, Report of foreign issuer4
05.06.Dr. Reddy's stock rises on biosimilar collaboration with Alvotech3
05.06.Dr. Reddy's Laboratories Ltd.: Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab)405Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE:...
► Artikel lesen
Weiter >>
96 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1